Condition: Lung Cancer Non-Small Cell Cancer (NSCLC) · Sponsor: University Hospital, Bonn
The hypothesis of the study is that induction immunochemotherapy, followed by surgery or chemoradiation and consolidation Durvalumab immunotherapy, can significantly improve event-free survival in patients with resectable or borderline resectable NSCLC at stage IIIA/B compared to existing treatment methods.
This description comes directly from the study's public registry record.
Eleni Gkika, Prof. Dr. med. · 0049 22825710353 · eleni.gkika@ukbonn.de
Always discuss trial participation with your own doctor first.
| University Hospital Freiburg | Freiburg im Breisgau, Baden-Wurttemberg, Germany | Recruiting |
| Klinikum Stuttgart | Stuttgart, Baden-Wurttemberg, Germany | Recruiting |
| University Hospital Gießen | Giessen, Hesse, Germany | Not Yet Recruiting |
| Johannes Wesling Klinikum Minden Mühlenkreiskliniken, Hämatologie und Onkologie | Minden, North Rhine-Westphalia, Germany | Recruiting |
| University Hospital Bonn | Bonn, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06810609